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Abstract
ZD6126 is a novel vascular-targeting agent that acts
by disrupting the tubulin cytoskeleton of an immature
tumor endothelium, leading to an occlusion of tumor
blood vessels and a subsequent tumor necrosis. We
wanted to evaluate ZD6126 in primary and metastatic
tumor models of human pancreatic cancer. Nude mice
were injected orthotopically with L3.6pl pancreatic
cancer cells. In single andmultiple dosing experiments,
mice received ZD6126, gemcitabine, a combination
of both agents, or no treatment. For the induction of
metastatic disease, additional groups of mice were in-
jected with L3.6pl cells into the spleen. Twenty-four
hours after a single-dose treatment, ZD6126 therapy
led to an extensive central tumor necrosis, which was
not seen after gemcitabine treatment. Multiple dosing
of ZD6126 resulted in a significant growth inhibition
of primary tumors and a marked reduction of sponta-
neous liver and lymph node metastases. Experimental
metastatic disease could be significantly controlled by
a combination of ZD6126 and gemcitabine, as shown
by a reduction of the number and size of established
liver metastases. As shown by additional in vitro and
in vivo experiments, possible mechanisms involve
antivascular activities and subsequent antiprolifera-
tive and proapoptotic effects of ZD6126 on tumor cells,
whereas direct activities against tumor cells seem un-
likely. These data highlight the antitumor and anti-
metastatic effects of ZD6126 in human pancreatic
cancer and reveal benefits of adding ZD6126 to stan-
dard gemcitabine therapy.
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Introduction
The importance of vascular network in tumor growth and
metastasis is now widely recognized and the ability to
interfere with this aspect of tumor survival offers a signifi-
cant therapeutic potential. Two key approaches have been
explored to specifically inhibit tumor blood supply [1,2]. The first
approach includes preventing the development of new tumor
blood vessels (angiogenesis) by using antiangiogenic agents,
thereby limiting tumor growth [2]. The second approach tries
to destroy existing abnormal tumor vessels by using specific
antivascular agents (vascular targeting) [3]. Vascular-targeting
drugs act largely by exploiting the structural and physiological
differences between normal and pathologic vasculature to
selectively disrupt and occlude immature tumor vessels. As a
large number of tumor cells depend on a relatively small
number of blood vessels, vascular targeting results in signifi-
cant tumor hypoxia and cell death, producing widespread
tumor necrosis [4,5].
ZD6126 is a novel vascular-targeting prodrug developed
by AstraZeneca (Macclesfield, UK), which is rapidly converted
in vivo by serum phosphatases to its active species ZD6126
phenol (N-acetylcolchinol), which binds to tubulin and causes
microtubular destabilization (Figure 1). Proliferating endo-
thelial cells, such as those of the tumor neovasculature, rely
on the tubulin cytoskeleton to maintain their shape. The bind-
ing of ZD6126 phenol to tubulin causes rapid morphologic
changes in the cell, leading to endothelial cell detachment,
tumor blood vessel occlusion, and massive tumor necrosis [6,7].
In contrast, mature endothelial cells of normal blood vessels
are less reliant on tubulin due to the presence of a well-defined
actin cytoskeleton, a mature basement membrane, and vessel-
associated pericytes, which are missing in pathologic tumor
vessels. Therefore, morphology of mature endothelial cells is
maintained under ZD6126 therapy. The mechanism of ZD6126
Abbreviations: IHC, immunohistochemistry; IFP, interstitial fluid pressure; IVM, in vivo video-
microscopy; i.p., intraperitoneal; HUVEC, human umbilical vein endothelial cell; MTD, maxi-
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action differs from other tubulin-binding agents, such as
colchicine and vinca alkaloids, as these agents are thought
to act primarily through a direct cytotoxic effect brought about
by mitotic arrest [8,9]. In different tumor xenograft models,
ZD6126 treatment has been shown recently to induce a
selective disruption of tumor blood vessels and an extensive
central tumor necrosis [10–15]. Dose–response studies
showed that these effects were seen at doses that were at
least 8- to 16-fold lower than the maximum tolerated dose
(MTD), demonstrating a wide therapeutic margin in those
animal models [10]. Despite the potent antivascular effects of
ZD6126 in the center of tumors, a thin rim of viable tumor
tissue is found at the periphery of tumors, where adjacent
normal vessels could still provide nutrients and oxygen to
peripheral tumor cells. These cells might rapidly reestablish
a new tumor mass. However, due to the high proliferation
rate of those cells, they might be still good targets for con-
ventional chemotherapy.
Because most cancer deaths in humans are due to
consequences of metastatic disease, it is important that
anticancer agents and combinations of drugs are not only
active in primary tumors but also prevent metastatic spread
or show efficacy in established metastatic disease. Pancre-
atic cancer, in particular, remains an unsolved health prob-
lem, with an overall 5-year survival rate of only 1% to 4% due
to an inability to detect this disease at early stages. Most of
the patients present with liver or lymph node metastases at
the time of diagnosis [16]. The aim of this study was to as-
sess the benefits of combining the new vascular-targeting
agent ZD6126 and the standard pyrimidine antimetabolite
gemcitabine in primary and metastatic human pancreatic
cancer. Orthotopic and heterotopic primary tumor models
and a model of established liver metastases were chosen
to study the efficacy of this combination therapy. Immuno-
histochemistry (IHC), in vivo videomicroscopy (IVM), and
in vitro proliferation assays were used to determine the
effects of ZD6126 on endothelial cells and human L3.6pl
pancreatic cancer cells [17].
Materials and Methods
Cell Lines and Culture Conditions
Human umbilical vein endothelial cells (HUVECs) were
isolated and cultured, as described before [18], and used
between the third and fifth passage. The highly proliferative
human pancreatic cancer cell line L3.6pl [17] was maintained
in Dulbecco’s minimal essential medium, supplemented with
5% fetal bovine serum, sodium pyruvate, nonessential amino
acids, L-glutamine, a two-fold vitamin solution (Life Technol-
ogies, Inc., Grand Island, NY), and a penicillin–streptomycin
mixture (Flow Laboratories, Rockville, MD), to constitute a
complete Dulbecco’s minimal essential medium. Monolayers
were maintained on plastic and incubated in 5% CO2 and
95% oxygen at 37jC. The culture was free of Mycoplasma
and pathogenic murine viruses and was maintained for no
longer than 12 weeks.
Animals and Compounds
Male athymic nude mice (Balb/c nu/nu) were purchased
from Charles River Laboratories (Sulzfeld, Germany, India-
napolis, IN). Animals were housed and maintained in laminar
flow cabinets under specific pathogen-free conditions at the
University of Regensburg (Regensburg, Germany) and used
in accordance with institutional and governmental guidelines
at 8 to 12 weeks of age.
ZD6126 was kindly provided by AstraZeneca and dis-
solved in a solution of 0.05% sodium carbonate in physio-
logical saline. Gemcitabine (Gemzar; Eli Lilly and Co.,
Indianapolis, IN) was obtained commercially. Antibodies
and reagents as follows were purchased: rat antimouse
CD31/PECAM-1 (Pharmingen, San Diego, CA); peroxidase-
conjugated goat antirat IgG [H+L] (Jackson Immuno Re-
search Laboratories, West Grove, CA); streptavidin–biotin
detection system (DakoA/S,Glostrup, Denmark); stable 3,3V-
diaminobenzidine (DAB; Research Genetics, Huntsville,
AL); 3-amino-9-ethylcarbazole (Biogenex Laboratories, San
Ramon,CA);Gill’s hematoxylin (SigmaChemicalCo., St. Louis,
MO); Ki67 (Dako A/S); an apoptosis detection kit for the ter-
minal deoxynucleotidyl transferase-mediated dUTP-biotin
end labeling (TUNEL) procedure (Promega, Madison, WI);
and an MTT cell viability assay kit for in vitro proliferation
assays (R&D Systems, Minneapolis, MN). Other consum-
ables used were as follows: OCT compound (Miles, Inc.,
Elkhart, IN); positively charged Superfrost slides (Fisher
Scientific Co., Houston, TX); and ProLong solution (Molecu-
lar Probes, Eugene, OR).
Cell Proliferation Assay
For an assessment of ZD6126 activity directed against
human pancreatic cancer cells and cultured endothelial cells,
we used an in vitro MTT cell viability assay, which was
conducted on cultured L3.6pl cells and HUVECs, as de-
scribed before [19,20]. Briefly, 15  103 cells/well were
plated in 96-well plates in complete medium. After 24 hours
of attachment, the active compound ZD6126 phenol was
added in different concentrations (0.001–1000 mM), and the
plates were incubated for another 48 hours. Cells were
washed with phosphate-buffered saline (PBS), the MTT
reagent was added according to the manufacturer’s recom-
mendations, and absorbance was measured at 570 nm. The
IC50 was defined as the drug concentration that causes
a 50% inhibition of cell proliferation. All experiments were
replicated three times.
Figure 1. Chemical structures of (A) the inactive prodrug ZD6126 (N-
acetylcolchinol-O-phosphate) and (B) its active metabolite ZD6126 phenol
(N-acetylcolchinol).
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Dose–Response Assays for Gemcitabine
Doses of ZD6126 and gemcitabine were chosen based
on the results of previous reports [10,13,21] and our own
preliminary experiments, respectively. In vitro, we confirmed
the efficacy of gemcitabine as a chemotherapeutic agent
against L3.6pl pancreatic cancer cells using the MTT cell
viability assay, as described before [20]. The IC50 value for
gemcitabine was 0.0487 mg/ml in this assay, demonstrating a
high sensitivity of L3.6pl cells. In contrast, AsPC human
pancreatic cancer cells showed IC50 values of 452.6 mg/ml
for gemcitabine. Moreover, in vivo dose–response experi-
ments were performed to evaluate the therapeutic effect
of gemcitabine on our animal models. Five mice per group
were treated biweekly with 500, 250, 125, 62, 31, 15.5, and
7.5mg/kg gemcitabine by intraperitoneal (i.p.) administration,
resulting in a growth inhibition of orthotopic L3.6pl tumors
by 65%, 58%, 55%, 46%, 36%, 31%, and 0.2%, respectively.
Hence, doses of 100 mg/kg gemcitabine were used for sub-
sequent experiments.
Single-Dose Therapy
For an evaluation of a single-dose therapy in established
primary pancreatic tumors, 24 mice were injected ortho-
topically with 1  106 viable human L3.6pl cells suspended
in 0.2 ml of PBS on day 0, as described previously [17,22].
After 14 days, when primary tumors were established (tumor
volume 125–512 mm3), animals received a single dose of
ZD6126 (150 mg/kg, i.p.; n = 6), a single dose of gemcitabine
(100 mg/kg, i.p.; n = 6), a combination of both agents at the
same doses (n = 6), or no treatment (n = 6). Animals were
sacrificed 24 hours after single-dose treatments, and tumors
were removed for histomorphologic examination (hema-
toxylin and eosin [H&E] staining).
Primary Tumor Model (Chronic Therapy)
For the assessment of tumor growth inhibition and
metastatic prevention through repeated dosage, another
40 mice were injected orthotopically with 1  106 L3.6pl
cells on day 0 [17]. On day 9, four mice were sacrificed,
and primary tumors with volumes of 64 to 216 mm3 but
without metastases were found, suggesting that, at that
time, medical treatment would be directed against well-
established but organ-confined pancreatic tumors and may
prevent metastatic disease. The treatment of the remain-
ing animals was started on the same day. Four groups of
animals received either ZD6126 for 5 days/week followed
by two treatment-free days (75 mg/kg per day, i.p.; n = 8);
or gemcitabine twice weekly (100 mg/kg, i.p; n = 10); or a
combination of both regimens (n = 8); or no treatment
(n = 10). All mice were sacrificed on day 25, as the control
animals became moribund. Pancreatic tumors were re-
moved and weighed, and five tumors per treatment group
were chosen randomly for further analysis. One part of
each of those tumors was fixed in formalin and embedded
in paraffin for immunohistochemical evaluation. The other
parts of the primary tumors were prepared for frozen
sectioning. Liver and lymph node metastases as well
as peritoneal carcinosis were assessed macroscopi-
cally and confirmed histologically by H&E staining. Tumor
nodules z1 mm in diameter were counted on the entire
liver surface.
Liver Metastasis Model (Chronic Therapy)
To evaluate the efficacy of palliative treatment in meta-
static disease, a liver metastasis model was used. For the
production of experimental liver metastases, 1  106 L3.6pl
cells were injected heterotopically into the spleen of an-
other 40 nude mice. After 14 days, four mice were sacri-
ficed, and all of them showed extended macroscopic liver
metastases. Thus, the treatment of the remaining animals
was started on day 14 with either ZD6126 (n = 9) or gem-
citabine (n = 9), or a combination of both agents (n = 9), or
no treatment (n = 9), using the same dosages as described
in the primary tumor model. Finally, mice were sacrificed
29 days after heterotopic tumor cell injection, as the control
animals became moribund. The liver and the spleen were
removed and weighed, and liver metastases were counted
on the entire liver surface, measured, and confirmed by
H&E staining.
Immunohistochemical Analyses
Immunohistochemical analyses of tumor vascularization
in primary tumors were performed on frozen sections from
the primary tumor model. Sections measuring 8 to 9 mm
were air-dried, fixed in cold acetone for 5 minutes, fixed
in acetone/chloroform for 5 minutes, fixed in acetone for
5 minutes, and thenwashed inPBS.After that, CD31 immuno-
histochemical staining was performed, as described pre-
viously, and microvessel density was assessed [23]. The
evaluation of tumor cell proliferation was performed using a
Ki67 monoclonal antibody. Therefore, paraffin-embedded
specimens of primary tumors were used, and 4- to 6-mm
sections were prepared on slides, dried overnight, deparaf-
finized in xylene, and rehydrated in 100%, 95%, and 80%
ethanol and PBS. Ki67 ‘‘antigen retrieval’’ was achieved
by microwaving sections for 5 minutes. Then IHC was
performed using a standard streptavidin–biotin method
with DAB as chromogen. Sections were analyzed micro-
scopically, and the numbers of positive staining cells were
counted. Paraffin-embedded tissues were also analyzed
for evidence of apoptosis by TUNEL fluorescein isothio-
cyanate (FITC) staining using a commercial apoptosis de-
tection kit. For all immunohistochemical studies, five sections
per tumor and five randomly chosen tumors per treatment
group were analyzed (25 sections per group). Microscopic
assessment was performed by two independent observers
who were blinded to all experimental data, through an anal-
ysis of 6 to 10 high-power fields (hpf) per section (hpf,
0.159 mm2).
IVM of Neovascularization
Tumor neovascularization in vivo was analyzed using
a window model, as described previously [24–26]. Briefly,
mice were implanted subcutaneously with 1  104 L3.6pl
cells in a transparent dorsal skinfold chamber on day 0. From
day 1, animals received ZD6126, 75 mg/kg, i.p., daily (n = 5)
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for a maximum of 10 days, or received no treatment (n = 5).
Tumor neovessels were assessed by a blinded observer
on days 2, 3, 5, 7, and 8 using IVM (Zeiss Axiotech Vario
microscope, Go¨ttingen, Germany). Then, average microvessel
density (combined vessel length [cm] / tumor area [cm2]) was
calculated out of 8 to 12 singlemeasurements using an Image
J software (Wayne Rasband, Version 1.25s; NIH, Bethesda,
MD) by generating horizontal grid lines for every 50 pixels.
Tumor vessels crossing the grid lines were individually mea-
sured, whereas vertically aligned vessels were not included
in the analysis. A conversion factor of 0.72 m/pixel was used
to calculate the actual vessel diameter.
Statistical Analysis
Pancreatic tumor weight, body weight, in vitro cell pro-
liferation (MTT assay), IHC quantification of CD31, Ki67 and
TUNEL, andmicrovessel densitymeasured by IVMwere com-
pared using one-way ANOVA with a Student–Newman–Keuls
multiple comparisons test (InStat 3.0 Statistical Software;
Graphpad Software, San Diego, CA). The relative rates of
liver and lymph node metastases within groups were com-
pared by Fisher’s exact test. All analyses were performed
with P < .05 considered as significant.
Results
Cell Proliferation Assay
A significant antiproliferative activity of ZD6126 phenol
on HUVECs could be already observed at concentrations of
0.1 mM (IC50 = 100 mM), but no significant inhibition of
proliferation was seen on L3.6pl cells at doses up to 100 mM
(Figure 2). The antiproliferative effects on L3.6pl cells were
seen exclusively at very high doses (IC50 = 1000 mM). How-
ever, this effect might be caused by an unspecific cytotoxic
activity of the agent at those concentrations.
Single-Dose Therapy
Twenty-four hours after a single-dose treatment with
ZD6126 (± gemcitabine), extensive tumor necrosis was
seen in six of six and in five of six mice, respectively
(Figure 3, C and D). Only a slim rim of viable tumor cells
was found in the periphery of those tumor nodules. In
contrast, no remarkable tumor necrosis was seen in controls
or under gemcitabine monotherapy (Figure 3, A and B).
Primary Tumor Model (Chronic Treatment)
Longer-term therapy appeared to be well tolerated, and
the assessment of body weight showed no significant dif-
ferences between all treatment groups (Table 1). Regarding
primary tumor growth, a significant reduction of pancre-
atic tumor weight was found in all treatment groups com-
pared to controls (Table 1). As expected out of preliminary
dose–response assays for gemcitabine, tumor growth inhi-
bition in vivo was about 50% compared to controls. How-
ever, tumor weight under combination therapy with ZD6126
and gemcitabine was significantly lower than in all other
treatment groups, reaching approximately 76% growth inhi-
bition compared to controls (control tumor weight 1320 ±
297 mg; combination therapy 443 ± 61) (Table 1). Concern-
ing metastatic prevention by multiple dosing therapy, mono-
therapy with gemcitabine had no significant effect on liver
and lymph node metastases. But treatment with ZD6126
alone or in combination with gemcitabine led to a sig-
nificant inhibition of liver and lymph node metastases com-
pared to gemcitabine monotherapy and controls (Table 1).
The reduction of lymph node metastasis was not depen-
dent on primary tumor size because gemcitabine mono-
therapy also led to a significant reduction of tumor weight
but did not inhibit lymphatic spread. The frequency of peri-
toneal carcinosis was significantly decreased follow-
ing treatment with gemcitabine, ZD6126, and combination
therapy (Table 1).
Figure 2. Effect of ZD6126 phenol on the in vitro proliferation of L3.6pl cells and HUVECs using the MTT cell viability test. The IC50 concentration was reached at
100 M for HUVECs and at 1000 M for L3.6pl cells, respectively. Significant antiproliferative effects: #L3.6pl, P < .01 (at least); *HUVECs, P < .05 (at least).
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Liver Metastasis Model (Chronic Treatment)
Regarding the palliative treatment of metastatic disease,
ZD6126 and gemcitabine induced a significant reduction of
heterotopic tumor mass after the implantation of pancreatic
tumor cells into the spleen (weight of spleen). Moreover, the
combination of both agents exhibited a significantly stronger
growth inhibition than either of the drugs alone (Figure 5A).
The size of established liver metastases (Figure 4) was lim-
ited by either ZD6126 or gemcitabinemonotherapy (Figure 5C),
butmetastatic tumor burden (weight of the liver) was primarily
decreased by gemcitabine or a combination therapy in this
model, whereas ZD6126 alone had no significant effect on
this parameter (Figure 5B). However, only combination
therapy significantly reduced the number of liver metastases
when compared to all other treatment groups (Figure 5D).
This indicates a therapeutic benefit in combining both agents
in our animal model.
Immunohistochemical Analyses
No difference in microvessel density and proliferation
index was found in gemcitabine-treated tumors when com-
pared to controls (Figure 6). However, ZD6126-treated
tumors (monotherapy and combination therapy) revealed
both significantly reduced vascularization (CD31) and cell
proliferation (Ki67) compared to gemcitabine treatment and
controls. Moreover, the TUNEL assay showed significantly
increased apoptotic cell deaths in tumors after gemcita-
bine, ZD6126, and combination therapy (340 ± 134; 363 ±
127; and 382 ± 52) compared with no treatment (132 ±
75) (Figure 7).
IVM Investigations
During ZD6126 treatment, dorsal skinfold chamber analysis
revealed a significant decrease of tumor neovascularization
compared with controls (Figure 8A). In vivo microvessel
Figure 3. Development of tumor necrosis 24 hours after single-dose treatment. (A) Control tumor; (B) gemcitabine, 100 mg/kg, i.p.; (C) ZD6126, 150 mg/kg, i.p.;
(D) ZD6126, 150 mg/kg, and gemcitabine, 100, mg/kg, i.p.; Arrow = necrotic area.
Table 1. Tumor Growth (Weight) and Metastatic Spread Following 21 Days of Treatment.
Therapy Pancreatic
Tumors
Liver
Metastases
Lymph Node
Metastases
Peritoneal
Carcinosis
Mean Tumor
Weight (mg) ± SD
Mean Body
Weight (g) ± SD
Control 10/10 6/10 10/10 7/10 1320 ± 297 19.8 ± 3.7
Gemcitabine 10/10 2/10 10/10 1/10* 687 ± 157y 19.1 ± 2.2
ZD6126 8/8 1/8z 2/8§,b 0/8# 541 ± 201y 18.5 ± 1.9
ZD6126 + gemcitabine 8/8 1/8z 3/8§,b 0/8# 443 ± 61y,b,** 17.0 ± 2.0
*P < .02 compared with control.
yP < .001 compared with control.
zP < .05 compared with control.
§P < .01 compared with control.
bP < .01 compared with gemcitabine.
#P < .005 compared with control.
**P < .03 compared with ZD6126.
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density was significantly reduced by ZD6126 after 1, 4, or
6 days of treatment (Figure 8B).
Discussion
ZD6126 is a potent tubulin-destabilizing agent that induces
rapid and reversible morphologic changes in proliferating
neoendothelia, whereas normal endothelial cells of non-
tumor tissues remain unaffected. In vivo, these conforma-
tional changes lead to endothelial cell detachment, tumor
vascular congestion, and resultant tumor necrosis, particu-
larly in the central tumor regions that are most reliant on
the tumor blood supply [6,10]. Administration of ZD6126
has shown potent antivascular effects at doses well below
the MTD, producing little or no classic antitubulin-mediated
toxicity (approximately 1/13 of the MTD of other tubulin-
binding agents such as combretastatin A-4 phosphate)
[6,27]. Moreover, pharmacokinetic studies in mice indicated
a short in vivo exposure of ZD6126 phenol due to its fast
elimination and, therefore, a rapid reversibility of the ZD6126
effect. Plasma concentration after a single-dose treatment
with ZD6126 decreased down to 1/100 of maximum levels
within 180 minutes [6].
Central parts of solid tumors are known to show some
resistance to conventional radiation therapy and chemo-
therapy due to tumor hypoxia and elevated interstitial fluid
pressure (IFP). Uncontrolled tumor angiogenesis and in-
creasing vascular permeability without an adequate lym-
phatic drainage lead to elevated IFP and subsequently to
lower tissue oxygenation and to reduced drug delivery to the
tumor center (e.g., radiosensitizers and chemotherapeutic
agents). These mechanisms consequently result in radia-
tion resistance and drug resistance [28,29]. Two different
therapeutic approaches are conceivably able to overcome
the problem of therapy resistance in central parts of solid
tumors. One might be the use of antiangiogenic agents, as
reviewed by Jain [29]. Certain antiangiogenic drugs have
been shown to normalize the abnormal structure and func-
tion of tumor vessels, thereby reducing IFP and induc-
ing more efficient oxygen delivery and drug delivery. The
other approach would be the occlusion of tumor vessels
by vascular-targeting agents such as ZD6126, inducing a
typical central tumor necrosis and leaving only a thin rim of
viable tumor cells at the periphery [6,10]. These remaining
tumor cells obtain blood supply from surrounding normal
vessels and, therefore, should be more sensitive to conven-
tional chemotherapy. Consequently, a combined approach
using a vascular-targeting agent and a chemotherapeutic
drug may provide a significant therapeutic benefit in solid
tumors. In the present study, ZD6126 was used for the first
time in combination with gemcitabine, which is the most rele-
vant chemotherapeutic agent for human pancreatic cancer.
In a variety of tumor models (including human xeno-
grafts derived from the breast, lung, colon, and stomach),
ZD6126 has been shown to induce extensive central
Figure 4. Extended macroscopic liver metastases 29 days after heterotopic
tumor cell injection into the spleen (control animal without treatment).
Figure 5. Palliative treatment of metastatic disease (liver metastasis model). (A and B) Tumor burden 29 days after the heterotopic implantation of pancreatic tumor
cells into the spleen. (C) Growth inhibition of established liver metastasis. (D) Decreasing number of liver metastases after the combination therapy only.
#Treatment versus control, P < .01 (at least); *combination versus ZD6126, P < .05 (at least); §combination versus gemcitabine, P < .05 (at least).
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tumor necrosis in both single and multiple dosing regimens
[10,11,13,14,30,31]—an action that could be confirmed for
human pancreatic cancer in the present study. ZD6126 was
found to be associated with a rapid necrosis of established
L3.6pl pancreatic tumors 24 hours after single-dose admin-
istration. This effect was not seen with gemcitabine therapy
alone, although gemcitabine is a potent cytotoxic agent in a
variety of solid tumor systems, and L3.6pl cells are highly
sensitive to gemcitabine but not to regular doses of ZD6126
phenol, as shown by MTT assays in vitro. This central ne-
crosis in L3.6pl tumors is likely to be the result of rapid tumor
vessel disruption as demonstrated by a massive early re-
duction of tumor vascularization in dorsal skinfold tumors
24 hours after the first ZD6126 administration. Direct effects
on tumor cells seem to be unlikely because the in vitro inhi-
bition of L3.6pl cell proliferation was exclusively seen at very
high doses of ZD6126 phenol (IC50 = 1000 mM). In contrast, a
significant alteration of endothelial cell morphology has been
described already at low concentrations (0.07 mM) [19], even
much lower than those needed to significantly inhibit endo-
thelial cell proliferation in our study (IC50 = 100 mM).
For multiple dosing regimens, we used a tumor model
where pancreatic primary tumors were well established
(64–216 mm3) but still organ-confined, to imitate the clinical
situation where curative therapy is possible if metastatic
disease could be prevented. Therefore, we started treatment
early on day 9 in this model. A significant antitumor activity
against the primary tumor was evident for both ZD6126 and
gemcitabine therapy. Tumor growth delay was obtained
most effectively by using a combination of both agents as
shown by the lowest primary tumor weight. However, tumor
weight obviously underestimates the antitumor effects of
ZD6126. Central necrotic areas preserve the measured
weight of a primary tumor to some extent without having an
impact on the tumor burden. The IVM procedure visualized
the multiple dosing effects of ZD6126, which included a rapid
and constant reduction in tumor vascularization starting
with the first day after the ZD6126 administration. Consis-
tently, histomorphologic and immunohistochemical analy-
ses revealed that ZD6126-mediated antitumor activity was
associated not only with central tumor necrosis but also
Figure 6. Immunohistochemical analysis of pancreatic tumors for CD31 and
Ki67 expressions (hpf, 0.159 mm2; original magnification, 100). Data
represent the mean values (± SD) of each treatment group (five sections per
tumor, five tumors per group, 6–10 hpf per section). #Treatment versus
control, P < .05 (at least); *combination versus gemcitabine, P < .05 (at least);
§ZD6126 versus gemcitabine, P < .05 (at least).
Figure 7. Apoptotic cell death in primary tumors: mean values (± SD) of TUNEL-FITC–positive cells in (A) control tumors, 132 ± 75; (B) ZD6126 treatment, 363 ±
127*; (C) gemcitabine treatment, 340 ± 134*; (D) ZD6126 + gemcitabine, 382 ± 52*. *Treatment versus control, P < .004 (at least).
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with a significant reduction in tumor vessel density and
also reduced tumor cell proliferation in viable parts of the
tumor. Both ZD6126 and gemcitabine treatments resulted in
increased apoptotic cell death in viable parts of those tumors
assessed by TUNEL assay. Pharmacokinetic results and
our own in vitro studies do not suggest that increased
apoptotic cell death and reduced cell proliferation in vivo
result from a direct effect of ZD6126 on tumor cells. It is, by
far, more likely that there was an indirect effect through tumor
hypoxia due to vascular destruction. Consistent with previ-
ous observations [22,23], gemcitabine therapy significantly
increased tumor cell apoptosis but affected neither the
fraction of proliferating tumor cells nor tumor vasculariza-
tion. Therefore, the synergistic activity of gemcitabine and
ZD6126 on tumor growth inhibition in primary tumor models
might be explained by the combination of different mecha-
nisms of action such as cytotoxic activity, tumor vessel oc-
clusion, and direct and indirect antiproliferative, proapoptotic,
and antiangiogenic effects.
Furthermore, multiple dosing of ZD6126 was associated
with a marked antimetastatic activity in primary tumors. Liver
and lymph node metastases could be prevented in more
than 3/4 of the animals by ZD6126 administration, and this ef-
fect was not enhanced by an additional treatment with gem-
citabine. Regarding hematogenous metastases such as liver
metastases, ZD6126might act through the destruction of tumor
vessels, thereby limiting the route of metastatic spread. Alter-
natively, amassive reductionof viable tumor volumebyZD6126
per se may be sufficient to decrease the number of metastatic
events. Lymph node metastases result from a tumor cell in-
vasion of lymphatic vessels and intralymphatic tumor growths.
Lymphatic tumor invasion and lymphangiogenesis occur at the
invasive edge of the tumor, where tumor cells proliferate and
get in contact with peritumoral lymphatics [32,33]. However,
this invasive edge of the tumor should then be identical to the
viable rim of proliferating tumor cells in our study. These cells
remained unaffected by ZD6126 therapy. Consequently, no
effect of ZD6126-dependent tumor necrosis on the frequency
of lymph node metastases should be expected. So far, there
have been no reports on ZD6126 effects on lymphatic vas-
culature. However, the significant reduction in lymph node
metastases seen in our study could possibly be caused by the
additional effects of ZD6126 on tumor-associated lymphatic
endothelial cells. A repeated dosing of gemcitabine alone
showed no apparent effect on spontaneous lymph node and
liver metastases and therefore did not improve the ZD6126
activity ofmetastatic prevention. Those antimetastatic data for
ZD6126 contrast with former studies of antiangiogenic agents
assessed in the same tumor model, where single-agent treat-
ment with PTK 787, DC101 (inhibitors of vascular endothelial
growth factor signaling), or PKI 166 (an inhibitor of epidermal
growth factor receptor signaling) did not affect the develop-
ment of metastases in L3.6pl pancreatic tumors [22,34].
These findings might indicate an important role of endothelial
cell–specific treatment to prevent metastatic spread.
To imitate the clinical situation of the palliative treat-
ment of advanced metastatic disease, we used a model of
experimental liver metastases. Here, extended metastatic
Figure 8. (A) Visualization of tumor neovasculature in dorsal skinfold chambers by IVM, 7 days after ZD6126 treatment or no treatment. (B) Neovascularization of
pancreatic tumors in dorsal skinfold chambers 1, 4, and 6 days after treatment initiation (n = 5) or no treatment (n = 5). Bars present the mean data from 8 to 12 IVM
measurements in four random areas per animal (± SD).
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disease could be created within 14 days. In contrast, spon-
taneous liver metastases would occur the earliest on day 23
after orthotopic tumor cell injection. This is about the time
when animals become moribund already due to a huge
pancreatic tumor mass [17]. In experimental metastatic dis-
ease, tumor burden could be significantly controlled by
ZD6126 and gemcitabine long-term treatment. In contrast to
spontaneous liver and lymph node metastases, gemcitabine
revealed significant antimetastatic activities in established
metastatic disease, as seen by a reduction of splenic and he-
patic tumor mass. The size of established liver metastases
was reduced by ZD6126 treatment as well as by gemcitabine
treatment, but only the combination of both agents could sig-
nificantly reduce the number of countable liver metastases.
This mechanism becomes plausible because the onset of
metastatic growth is a very sudden event in this tumor model,
and established livermetastases rapidly gain an efficient blood
supply. Both cytotoxic effects (gemcitabine) and antivascular
effects (ZD6126) could possibly inhibit the growth of estab-
lished metastases. However, only the combination of both
agents may reduce the number of metastases, probably by
eliminating small ones or at least by preserving them in a very
early, uncountable, and possibly ‘‘dormant’’ cell cluster status.
The mechanism of ZD6126 action makes it particu-
larly attractive to use this drug in combination with other
anticancer approaches, such as certain cytotoxic agents
and radiation therapy, as these therapies are most effective
against well-vascularized and well-oxygenated areas of the
tumor, such as the peripheral rim. Correspondingly, it has
been shown that the antitumor effect of ZD6126 could be
enhanced when it is used in combination with cisplatin,
paclitaxel, and radiation therapy [11,13,14,35]. Gemcitabine
is currently licensed for the treatment of locally advanced
and metastatic adenocarcinomas of the pancreas. The pres-
ent study demonstrates for the first time the antitumor
and antimetastatic effects of ZD6126 in human pancreatic
cancer models. Although metastatic prevention could not be
achieved by gemcitabine monotherapy in this study, our re-
sults highlight the therapeutic benefits of combining ZD6126
and gemcitabine in advanced metastatic disease, where
synergistic effects could be observed compared to an exclu-
sive administration of either drug.
Conclusion
Our studies confirm previous observations of the single-
dose effect of ZD6126, resulting in a central necrosis of es-
tablished orthotopic pancreatic tumors. Longer-term therapy
with repeated doses of ZD6126 in pancreatic tumor models
appeared to be well tolerated and resulted in a significantly
reduced primary tumor size and in the reduction of lymph
node and liver metastases. As shown by in vitro and in vivo
experiments, possible mechanisms of ZD6126 involve anti-
vascular activity and subsequent antiproliferative and pro-
apoptotic effects, whereas a direct activity against tumor
cells seems unlikely. Although metastatic prevention by gem-
citabine was inefficient in orthotopic tumor settings, the growth
inhibition of primary tumors and experimental liver metastases
were most obvious after the combination of ZD6126 and
gemcitabine. This observation highlights the therapeutic po-
tential of combining agents with differing mechanisms of ac-
tion, particularly when different cell populations within the
tumor are targeted (endothelial and tumor cells). Experimental
approaches to combine vascular-targeting agents with stan-
dard gemcitabine therapy need to be further evaluated.
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